Results 171 to 180 of about 21,799 (237)

Real-world outcomes of ranibizumab biosimilars in various retinal diseases: a Korean multi-center experience-ROSE Korea Study. [PDF]

Sci Rep
Song JR, Park UC, Lee CS, Cho JJ, Kim JY, Baek SC, Jeong A, Sharma A, Kim JH, Sagong M, Woo SJ, International Retina Biosimilar Study Group (Inter BIOS Group).   +11 more
europepmc   +1 more source

Barriers to Biosimilar Approval: Creating Clarity Through the Publication of Product-Class Specific Guidances [PDF]

, 2016
McEnrue, Martin
core  

Out-of-Pocket Spending for Biologic Drugs After Biosimilar Competition for Medicare Patients.

JAMA Netw Open
Riegler JS, Kesselheim AS, Rome BN.
europepmc   +1 more source

Savings from biosimilars and Medicare formulary access. [PDF]

Health Aff Sch
Axelsen K, Courmier D, Bai G, Maini L.
europepmc   +1 more source

Safety outcomes in 2132 Danish patients with inflammatory arthritis treated with biosimilar infliximab (GP1111) in routine care. [PDF]

Ther Adv Musculoskelet Dis
Nabi H, Jensen KY, Westermann R, Hendricks O, Jensen DV, Loft AG, Just SA, Pedersen JK, Danebod K, Munk HL, Kristensen S, Colic A, Thygesen PH, Ammitzbøll M, Chrysidis S, Mehnert F, Steen Krogh N, Hetland ML, Glintborg B.   +18 more
europepmc   +1 more source

Biosimilar [PDF]

, 2020
openaire   +1 more source

Effectiveness and safety of adalimumab biosimilar in bio-naive patients with inflammatory bowel disease: a real-life multicenter observational study comparing ABP501, SB5, MSB11022, GP2017, and FKB327. [PDF]

Crohns Colitis 360
Regueiro C, Vázquez Rey MT, Bastón-Rey I, Galego MA, Campos AC, Baz López AM, Arriero GM, Ruiz Barcia MJ, Villaamil PV, EIGA.   +9 more
europepmc   +1 more source

Current status and trends of anti-tumor biosimilars in China from 2019 to 2023: A cross-sectional analysis. [PDF]

Saudi Pharm J
Shan H, Guo Z, Ye X, Du Q, Liu J, Wang M.   +5 more
europepmc   +1 more source

Switching Between Epoetins: A Practice in Support of Biosimilar Use [PDF]

, 2016

core   +1 more source

Perforating dermatosis in a young female patient receiving adalimumab biosimilar CTP-17 for chronic plaque psoriasis: A case report. [PDF]

SAGE Open Med Case Rep
Lozito A, Baravalle S, Poddine G, Colato C, Carletto A, Fracassi E, Bellinato F, Girolomoni G, Gisondi P.   +8 more
europepmc   +1 more source